Understanding Obesity: The Causes, Effects, and Treatment Options
|
|
- Lindsay Hensley
- 6 years ago
- Views:
Transcription
1 Understanding Obesity: The Causes, Effects, and Treatment Options Jeffrey Sicat, MD, FACE Virginia Association of Clinical Nurse Specialists September 29, 2017 Objectives By the end of this discussion, you should be able to: Understand and appreciate multiple factors contribute to weight gain Discuss the physiology of weight regulation Understand the role of weight loss medications Outline Background and Epidemiology of Obesity Defining Obesity as a Chronic Complex Disease Treatment Options Pharmacology of Obesity Management 1
2 The causes of weight gain are multifactorial Strategies for Weight Loss What is more effective for weight loss? a) Diet b) Exercise The majority of diets do not cause significant sustained weight loss 2
3 Most people who lose regain The body s hormone system adapts to weight loss and tries to regain Multiple Complex Interactions Among Hormonal & Neural Pathways Regulate Food Intake 3
4 Treating obesity requires control of hunger NIH Guidelines for Weight Management BMI Range Treatment Diet and Nutrition Exercise & Activity Behavior Therapy Overweight Overweight Obesity (Class 1) Obesity (Class 2) Obesity (Class 3) 40 or higher Pharmacotherapy (Comorbidities) Surgery (Lap Band with Comorbidities) (With Comorbidities) Newer Anti-Obesity Drugs--- Drug Name (Generic Name) Drug (Brand Name) Approved Lorcaserin Belviq June 2012 Phentermine/topiramate XR Qsymia July 2012 Bupropion/Naltrexone Contrave October 2014 Liraglutide (high dose 3.0 mg) Saxenda December
5 --- 4 Newer Anti-Obesity Drugs--- FDA Approved Indications and Usage Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial BMI of: 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weightrelated comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia) Limitations of Use: Effects on cardiovascular morbidity and mortality have not been established The safety and effectiveness in combination with other products intended for weight loss, including prescription, OTC, and herbal supplements has not been established Pregnancy Category X Qsymia (phentermine and topiramate extended release) Qsymia (phentermine/topiramate XR) XR Phentermine: Reduces Hunger Lasting 6-12 hrs Can be stimulating Topiramate XR: Hunger / Satiety / Other Mechanisms? Long Acting / Extended Release Non-stimulating Allison et al. EQUIP Study. Obesity 2011;20:
6 Qsymia (phentermine/topiramate XR) Qsymia (phentermine/topiramate XR) Allison et al. EQUIP Study. Obesity 2011;20: Qsymia (phentermine/topiramate XR) Completers were 84%, 67%, 48% compared to the above which were ITT Allison et al. EQUIP Study. Obesity 2011;20:
7 Qsymia (phentermine/topiramate XR) Garvey et al. SEQUEL Study. Am J Clin Nutrition 2012; 95: Qsymia (phentermine/topiramate XR) XR Side Effects that were significantly more than placebo: Phentermine: Dry Mouth (19%) Constipation (16%) Insomnia (9%) Topiramate XR: Paresthesias (20%) Dizziness (9%) Dysgeusia (9%) Allison et al. EQUIP Study. Obesity 2011;20: Qsymia (phentermine/topiramate XR) Factors to consider: Qsymia is the most potent medication option for weight loss but Qsymia is Pregnancy Category X and can cause birth defects REMS (Risk Evaluation and Mitigation Strategy) Program Counsel women on the risk of orofacial clefts in infants exposed to Qsymia during the first trimester of pregnancy Topiramate can cause cleft palate (1-4%) if taken in 1 st trimester Women of childbearing years MUST be counseled on effect birth control if using this medication Recommend having a pregnancy before starting and monthly while on Qsymia 7
8 Belviq (lorcaresin) Belviq (lorcaserin) FDA Approved June 2012 Appetite suppressant non stimulating Selectively binds to serotonin (5-HT2c) receptors to reduce appetite Does not bind to serotonin (5-HT2b) receptors which could potentially cause valvulopathy (i.e. fenfluramine) Smith et al. BLOOM Study Group. NEJM 2010;363: Belviq (lorcaserin) 5-HT-2c receptors present in the hypothalamus Stimulation reduces hunger BELVIQ SELECTIVELY BINDS 5-HT-2b receptors present in the heart Stimulation can cause valvulopathy FENFLURAMINE MILDLY BOUND Smith et al. BLOOM Study Group. NEJM 2010;363:
9 Belviq (lorcaserin) Average 5.8% weight reduction Smith et al. BLOOM Study Group. NEJM 2010;363: Belviq (lorcaserin) Attained medically significant weight loss Smith et al. BLOOM Study Group. NEJM 2010;363: Belviq (lorcaserin) Factors to consider: Belviq selectively binds to the 5-HT2c receptor to reduce appetite Valvulopathy was not seen greater than placebo up to 2 years It is the only non-stimulating appetite suppressant Side effects noted were: URIs, headaches, dizziness, nausea Exluded from the trials (i.e. not studied) included: Patients with moderate to severe mitral valve regurgitation or in patients with any aortic regurgitation Patients with depression or psychiatric disease requiring psychiatric medications in the last 2 years Belviq Package Insert accessed 4/15/16. 9
10 Belviq (lorcaserin) Warnings and Precautions: Belviq is a serotonergic drug. The development of potentially life threatening serotonin syndrome or neuroleptic malignant syndrome-like reactions have been reported with serotonin agents especially in combination (hyperthermia, muscle rigidity, autonomic instability, AMS) Triptans and dextromethorphan can increase levels of Belviq Belviq can inhibits CYP 2D6-mediated drug metabolism thus increasing levels of medications metabolized by cytochrome P450 2D6 can increase levels of fluoxetine, paroxetine, sertraline, duloxetine In patients with type 2 diabetes, risk of hypoglycemia reduced A1c by 0.9% Rare priapism (avoid in conditions that might predispose including sickle cell, multiple myeloma, peyronies ) Belviq Package Insert accessed 4/15/16. Contrave (bupropion / naltrexone) 10
11 Contrave Warning SUICIDALITY AND ANTIDEPRESSANT DRUGS CONTRAVE is not approved for use in the treatment of major depressive disorder or other psychiatric disorders. CONTRAVE contains bupropion, the same active ingredient as some other antidepressant medications (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL and APLENZIN). Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older. In patients of all ages who are started on CONTRAVE, monitor closely for worsening, and for the emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. CONTRAVE is not approved for use in pediatric patients Contrave 1 year weight loss was 8% in completers Contrave 1 yr weight loss was 12% in completers + aggressive BMOD 11
12 Contrave Saxenda (liraglutide 3.0 mg) 12
13 GLP-1 Mechanism of Action 1. Glucose dependent insulin secretion Restoration of 1 st phase insulin response 2. Reduced hepatic gluconeogenesis 3. Delayed gastric emptying 4. Central reduction of hunger / Weight loss Victoza (liraglutide) (high dose) Astrup et al. International Journal of Obesity. 2012;36: Saxenda 3.0 mg GLP-1 Therapy 1 yr weight loss was 9% in completers Pi-Sunyer et al. SCALE Obesity and Pre-Diabetes Trial. NEJM. 2015;373:
14 Saxenda 3.0 mg GLP-1 Therapy Pi-Sunyer et al. SCALE Obesity and Pre-Diabetes Trial. NEJM. 2015;373: How to start and adjust Saxenda Saxenda Warning WARNING: RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether Saxenda causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined Saxenda is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the risk of MTC with use of Saxenda and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Saxenda Saxenda Package Insert accessed 4/15/16. 14
15 Saxenda Risks and Precautions Adverse Symptoms: Nausea Constipation / diarrhea Diarrhea Vomiting Dyspepsia Hypoglycemia (in T2DM pts on sulfonylureas) Dizziness 9.8% Discontinuation Rate due to Adverse Symptoms Saxenda Package Insert accessed 4/15/16. Saxenda REMS Program 1) Potential risk of Medullary Thyroid Cancer Liraglutide causes dose dependent and treatment duration dependent thyroid C-cell tumors in at clinically relevant doses in both genders of rats and mice It is unknown whether Saxenda causes thyroid C-cell tumors, including medullary thyroid cancer in humans as the human relevance has not been determined 2) Risk of Acute Pancreatitis: Based on spontaneous postmarketing reports acute pancreatitis has been observed in people treated with liraglutide In clinical trials there were more cases of pancreatitis in patients treated with Saxenda than placebo Saxenda Package Insert accessed 4/15/16. Conclusions Obesity is a chronic, relapsing, progressive disease Weight gain and obesity have a tremendous affect on our physical and mental health and on our healthcare system Diet is more effective than exercise for weight loss Weight gain is caused by multiple factors Many common medications can cause weight gain The majority of people attempting to lose weight do not succeed with diet and exercise alone Multiple factors beyond a patients control increase hunger and cravings and the desire to eat 15
16 Conclusions Successful long term weight loss requires control of hunger Hunger control can be achieved: Nutritionally, Behaviorally, Pharmacologically, or Surgically Medications enhance the amount of weight lost If diet and exercise fail patients may benefit from a complete medical evaluation to evaluate and treat potential other causes of weight gain Four new medications have been approved since 2012 for chronic weight management Due to its complexity, the treatment of obesity requires a chronic, long-term, multimodal approach QUESTIONS? Jeffrey Sicat, MD, FACE jeffsicat@gmail.com 16
WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM?
WEIGHT LOSS/MANAGEMENT IS IT JUST ANOTHER PIPE DREAM? THE OBESITY MEDICINE ASSOCIATION S DEFINITION OF OBESITY Obesity is defined as a chronic, relapsing, multi-factorial, neurobehavioral disease, wherein
More informationI. ALL CLAIMS: HEALTH CARE PROFESSIONALS
HCP Prescribing Information Date/Version January 2015 Version 2 Page: 1 of 5 I. ALL CLAIMS: HEALTH CARE PROFESSIONALS Indications and Usage Saxenda (liraglutide [rdna origin] injection) is indicated as
More informationThe New Trend of Anti-Obesity Drug
2016 년대한당뇨병학회춘계학술대회 The New Trend of Anti-Obesity Drug MIN-SEON KIM ASAN MEDICAL CENTER Conflict of Interest Nothing to declare Index Introduction: Obesity Epidemiology, Pathophysiology and Comorbidity
More informationWhen Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity
When Diet and Exercise Aren t Enough: Pharmacologic Management of Obesity Casey Bonaquist, DO Saturday, April 30 th, 2016 17 th Annual Primary Care & Cardiovascular Symposium Learning Objectives After
More informationAn Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD
An Individualized Approach to Optimize Obesity Treatment Louis Aronne, MD Sanford I. Weill Professor of Metabolic Research Director of the Comprehensive Weight Control Program Weill Cornell Medical College
More informationObesity Pharmacotherapy: Options and Applications in Clinical Practice. Scott Kahan, MD, MPH
Obesity Pharmacotherapy: Options and Applications in Clinical Practice Scott Kahan, MD, MPH Obesity Pharmacotherapy Few providers prescribe pharmacotherapy. Few patients use pharmacotherapy. Pharmacotherapy
More informationComplete the Qsymia Healthcare Provider Training Program in 2 easy steps:
Overview FDA has required a Risk Evaluation and Mitigation Strategy (REMS) for Qsymia so that healthcare providers can be informed about the increased risk of teratogenicity associated with Qsymia therapy.
More informationWhat Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels?
What Are the Effects of Weight Management Pharmacotherapy on Lipid Metabolism and Lipid Levels? Daniel Bessesen, MD Professor of Medicine University of Colorado School of Medicine Chief of Endocrinology,
More informationReduce hunger and help control cravings with CONTRAVE
Reduce hunger and help control cravings with CONTRAVE Understanding and identifying patients who are ready to start their weight-loss journey with CONTRAVE is key to helping them reach their weight-loss
More informationPharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018
Pharmacotherapy IV: Liraglutide for Chronic Weight Management SARAH CAWSEY MD, FRCPC 2 ND ANNUAL OBESITY UPDATE SEPTEMBER 22, 2018 Disclosures Faculty Assistant Clinical Professor, Department of Medicine,
More informationOverview Purpose Complete the Qsymia Pharmacy Certification in 3 easy steps:
Overview The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for Qsymia to ensure the benefits of Qsymia outweigh the increased risk of teratogenicity.
More informationOverview. Purpose. Qsymia (phentermine and topiramate extended-release) capsules CIV Pharmacy Training Program
Qsymia (phentermine and topiramate extended-release) capsules CIV Pharmacy Training Program Overview The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS)
More informationObesity: Pharmacologic and Surgical Management
Obesity: Pharmacologic and Surgical Management ADRIENNE YOUDIM, MD, FACP ASSOCIATE PROFESSOR OF MEDICINE, UCLA ASSISTANT PROFESSOR OF MEDICINE, CEDARS SINAI MEDICAL CENTER JANUARY 2018 Defining Obesity
More informationLearning Objectives. Currently Available Options. Update on Weight Loss Pharmacotherapy. Dan Bessesen, MD
Update on Weight Loss Pharmacotherapy Dan Bessesen, MD Daniel.bessesen@ucdenver.edu Learning Objectives List the medications that are currently available for the treatment of obesity, describe their mechanisms
More informationWHAT S THE SKINNY ON WEIGHT LOSS MEDICATION SAFETY? January 25, 2019 Pennsylvania Pharmacists Association
WHAT S THE SKINNY ON WEIGHT LOSS MEDICATION SAFETY? January 25, 2019 Pennsylvania Pharmacists Association MEGAN N DUNLOP, PHARMD, CTTS CLINICAL PHARMACIST, UPMC COMMUNITY PROVIDER SERVICES LEARNING OBJECTIVES
More informationOverview of Management of Obesity
Overview of Management of Obesity Srividya Kidambi, MD, MS Division of Endocrinology, Metabolism, and Clinical Nutrition Medical College of Wisconsin, Milwaukee, WI I have nothing to disclose. Objectives
More informationLorcaserin (Belviq ) Rimonabant 2008 Sibutramine (Reductil, ) (World Health organization, WHO) 1996 WHO Orlistat (Xenical, )
(World Health organization, WHO) 1996 WHO (Body mass index, BMI)2427 kg/m 2 27 kg/m 2 25% 30%2013-2014 43.5%(48.9%38.3%) (AACE/ACE)2016 1 BMI 27 kg/m 2 BMI 35 kg/m 2 (The Food and Drug Administration,
More informationManagement of Obesity. Objectives. Background Impact and scope of Obesity. Control of Energy Homeostasis Methods of treatment Medications.
Medical Management of Obesity Ben O Donnell, MD 1 Objectives Background Impact and scope of Obesity Control of Energy Homeostasis Methods of treatment Medications 2 O'Donnell 1 Impact of Obesity According
More informationDonna H Ryan, MD, FACP Pennington Biomedical Research Center Baton Rouge, LA.
Donna H Ryan, MD, FACP Pennington Biomedical Research Center Baton Rouge, LA Donna.Ryan@pbrc.edu National Summit on Health Disparities April 22, 2013 Disclosure Dr. Ryan has served as an advisor to Nutrisystem
More informationThe ABCDs of Obesity
The ABCDs of Obesity Adipose Based Chronic Disease Michael A. Bush, M.D. Clinical Chief, Division of Endocrinology Cedars-Sinai Medical Center Clinical Associate Professor, Geffen School of Medicine, UCLA
More informationAnti-Obesity Agents Drug Class Prior Authorization Protocol
Anti-Obesity Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: March 1, 2018 This policy has been developed through review
More informationRealistic Expectations: Drugs in the Treatment of Obesity. Lora Cotton, D.O. January 20, 2013
Realistic Expectations: Drugs in the Treatment of Obesity Lora Cotton, D.O. January 20, 2013 Overview Approach FDA approved agents will be covered FDA approval guidelines Candidates Expectations Mechanisms,
More informationFDA approves Belviq to treat some overweight or obese adults
FDA approves Belviq to treat some overweight or obese adults Silver Spring, MD, USA (June 27, 2012) - The U.S. Food and Drug Administration today approved Belviq (lorcaserin hydrochloride), as an addition
More informationWithout Background for printing as Pocket Reference
Without Background for printing as Pocket Reference Diabetes Prevention Program 1 LOOK AHEAD 3 Multi-center trial in patients with impaired glucose tolerance Weight loss of 7% reduced the rate of progression
More informationCONTRAVE Summary Brand Usage Guidelines for Third Parties
CONTRAVE We thank you for your interest in using the CONTRAVE brand assets to help educate patients struggling to lose weight. This summary document is for reference only. In accordance with the CONTRAVE
More informationSyllabi/Slides for this program are a supplement to the live CME session and are not intended for other purposes.
1:55-2:4pm Medical Management of Obesity: Lifestyle, Medicine, and Surgery SPEAKER Osama Hamdy, MD, PhD, FACE Disclosures The following relationships exist related to this presentation: Osama Hamdy, MD,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1172-3 Program Prior Authorization - California and New York Regulatory Program - Weight Loss Medication Includes both brand and
More informationClinical Policy: Weight Loss Reference Number: CP.CPA.200 Effective Date: Last Review Date: Line of Business: Commercial - HNCA
Clinical Policy: Reference Number: CP.CPA.200 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial - HNCA Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Weight Loss Reference Number: CP.CPA.197 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.197 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationMedical Management of Obesity: Multidisciplinary Team and Pharmacologic Therapy. Shelby Sullivan University of Colorado School Of Medicine
Medical Management of Obesity: Multidisciplinary Team and Pharmacologic Therapy Shelby Sullivan University of Colorado School Of Medicine Disclosures Research Support / Grants R01DK094483-02 Klein/Mittendorfer
More informationObesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.
Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, 2018 10:15 a.m. 11:00 a.m. Type 2 diabetes mellitus (T2DM) is closely associated with obesity, primarily through the link
More informationHealthy weight 18.5 to <25. Diabetes Dispatch. Overweight 25 to <30. Obese class I 30 to <35. Obese class II 35 to <40
A L A S K A N A T I V E D I A B E T E S T E A M Diabetes Dispatch Volume 10, Issue 4 Winter 2015 T he American Medical Association, the World Health Organization, and the US Food and Drug Administration
More informationSaxenda (liraglutide injection 3 mg) Patient Information
Who Is Saxenda For? Saxenda is a medication for chronic weight management. It is for people with overweight and weight-related complications or obesity. It is meant to be used together with a lifestyle
More informationManagement of obesity
From Behavior Modification through Pharmacotherapy to Surgery an Emphasis on the Team Approach Scott D. Isaacs, M.D., F.A.C.P., F.A.C.E. drisaacs@atlantaendocrine.com Understand the physician s role in
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationPutting It in Perspective Using Medications for Chronic Weight Management. Donna H. Ryan, MD Pennington Biomedical Research Center
Putting It in Perspective Using Medications for Chronic Weight Management Donna H. Ryan, MD Pennington Biomedical Research Center ryandh@pbrc.edu Why Use Medications? Medications help patients lose more
More informationBrand Name: Belviq. Generic Name: lorcaserin hydrochloride. Manufacturer 3 : Eisai Inc. Drug Class 1,2 : Serotonin 5-HT 2C Receptor Agonist
Brand Name: Belviq Generic Name: lorcaserin hydrochloride Manufacturer 3 : Eisai Inc. Drug Class 1,2 : Serotonin 5-HT 2C Receptor Agonist Uses: Labeled Uses 1,2,3,4,5 : Adjunctive treatment for obesity
More informationTreatment of Obesity SAJIDA AHAD MERCY GENERAL SURGERY
Treatment of Obesity SAJIDA AHAD MERCY GENERAL SURGERY Objectives 1. Learn classification and evaluation of overweight and obese patient 2. Discuss impact of voluntary weight loss on morbidity and mortality
More informationCravings are one of the main reasons diets fail
? Did you KNOW Cravings are one of the main reasons diets fail Help control your cravings and lose weight with CONTRAVE Actual patient. Results not typical. Across three studies, 46% of patients taking
More information9 out of 10 people struggle with food cravings while dieting?
CONTRAVE IS THE #1 PRESCRIBED WEIGHT-LOSS BRAND* DID YOU KNOW... 9 out of 10 people struggle with food cravings while dieting? Help control your cravings and lose weight with CONTRAVE The exact neurochemical
More information9 out of 10 people struggle with food cravings while dieting?
CONTRAVE IS THE #1 PRESCRIBED WEIGHT-LOSS BRAND* DID YOU KNOW... 9 out of 10 people struggle with food cravings while dieting? Help control your cravings and lose weight with CONTRAVE The exact neurochemical
More informationSafety and Tolerability of Medications Approved for Chronic Weight Management
19. Gadde KM, Allison, DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in
More informationModest weight loss of 5% to 10%
These 4 cases illustrate how weight loss drugs including the 4 newest can be integrated into a treatment plan that includes diet, exercise, and behavior modification Katherine H. Saunders, MD; Alpana P.
More informationObesity Management in Type 2 Diabetes
Obesity Management in Type 2 Diabetes Clare J. Lee, MD, MHS Assistant Professor of Medicine, Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins University Disclosures None Objectives Describe
More informationDisclosures. Objectives. Impact of Obesity in Primary Care Practice and What To Do About It. Intuitive Surgical. Consultant
Disclosures Intuitive Surgical Consultant Stephen Archer, MD, FACS, FASMBS Director, Bariatric Surgery, St. Charles Medical Center Bend, OR Grand Rounds June 15, 2018 2 Objectives Impact of Obesity in
More informationFor Personal Use Only. Any commercial use is strictly prohibited. Role of glucagon-like peptide 1 receptor agonists in management of obesity
Role of glucagon-like peptide 1 receptor agonists in management of obesity Diana Isaacs, Pharm.D., BCPS, BC-ADM, CDE, Chicago State University, Chicago, IL, and Oak Lawn VA Clinic of Edward Hines Jr. VA
More information1 Mechanick JI, Garber AJ, Handelsman Y, Garvey WT. Endocr Pract. 2012;18: Depression. Cancer. Gallbladder Disease
Percent 4 3 2 1 Obese Overweight Extremely obese Note: Age-adjusted by the direct method to the year 2 US Bureau of the Census using age groups 2 39, 4 59, and 6 74 years. Pregnant females excluded. Overweight
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationFaculty/Presenter Disclosure
Weight loss & Obesity WHAT S NEW & EXCITING? Tina Korownyk Dept of Family Medicine, UofA Faculty/Presenter Disclosure Faculty/Presenter: Tina Korownyk Relationships with commercial interests: None 1 Drowning
More informationUpdate on the Recent Advances in Obesity Management. Benjamin O Donnell, MD Oct 5 th, 2018
Update on the Recent Advances in Obesity Management Benjamin O Donnell, MD Oct 5 th, 2018 Objectives Background Control of Energy Homeostasis Approach to Diet and Exercise Medications Recently Approved
More informationReview of Pharmacologic Weight Loss Medications in a Patient-Centered Medical Home
604858PMTXXX10.1177/8755122515604858Journal of Pharmacy TechnologyCostello et al research-article2015 Case report Review of Pharmacologic Weight Loss Medications in a Patient-Centered Medical Home Journal
More informationWhat s the Skinny?: An Update on Medications for Weight Management
What s the Skinny?: An Update on Medications for Weight Management Katura C. Bullock, PharmD, BCPS Associate Professor UNT System College of Pharmacy SESSION OBJECTIVES 1. Recognize the prevalence of obesity
More informationFaculty Disclosures. Vera Tarman, MD, Author:
Faculty Disclosures Vera Tarman, MD, Author: Food Junkies: The Truth About Food Addiction (book) Dangerous Liaisons: Comfort and Food (DVD) Biology of Addiction, Biology of Recovery (DVDs) Standard Treatments
More informationNavigating the new weight loss medications Jacqueline Jordan Spiegel, MS, PA-C, DFAAPA Associate Professor Midwestern University
Navigating the new weight loss medications Jacqueline Jordan Spiegel, MS, PA-C, DFAAPA Associate Professor Midwestern University Objectives Discuss the evolution of obesity as a diagnosis and disease.
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SAXENDA safely and effectively. See full prescribing information for SAXENDA. SAXENDA (liraglutide
More informationUpdate on Treating Obesity: A Multidisciplinary Approach. Marie Harkins, FNP BC, CDE Cayuga Center for Healthy Living
Update on Treating Obesity: A Multidisciplinary Approach Marie Harkins, FNP BC, CDE Cayuga Center for Healthy Living Objectives 1. Define obesity as a disease 2. List the stepwise approach to obesity treatment
More informationThe US FDA, EMA and our TGA use these cutpoints in assessing drug efficacy. Disclosures: Professor John B Dixon
Obesity: The Role of Pharmacotherapy Professor John B Dixon, MBBS PhD Professorial Research Fellow Head, Clinical Obesity Research Baker IDI Heart & Diabetes Institute Melbourne, Australia The Annual Women
More informationDisclosures. Start the Conversation. Agenda. Behavioral and Medical Approaches for Obesity Treatment 10/18/2014
Disclosures Behavioral and Medical Approaches for Obesity Treatment Scott Kahan, MD, MPH Director, National Center for Weight and Wellness Clinical Director, Strategies To Overcome and Prevent (STOP) Obesity
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More informationMEDICAL MANAGEMENT 101
MEDICAL MANAGEMENT 101 Christopher Still, DO, FACN, FACP Medical Director, Center for Nutrition & Weight Management Director, Geisinger Obesity Research Institute Geisinger Health Care System Your Weight
More informationBupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL
Bupropion Generic names Available brands Available strengths and formulations Available in generic Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL 75-mg
More informationPharmacotherapy III: Naltrexone/Bupropion(Contrave ) for Chronic Weight Management. Renuca Modi MD CCFP 2 nd ANNUAL OBESITY UPDATE September 22, 2018
Pharmacotherapy III: Naltrexone/Bupropion(Contrave ) for Chronic Weight Management Renuca Modi MD CCFP 2 nd ANNUAL OBESITY UPDATE September 22, 2018 COI Faculty: Renuca Modi, MD, CCFP Diplomate of the
More informationFULL PRESCRIBING INFORMATION: CONTENTS* BOXED WARNING: RISK OF THYROID C CELL TUMORS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SAXENDA safely and effectively. See full prescribing information for SAXENDA. SAXENDA (liraglutide)
More information2. Is the request for Alli, Xenical or Belviq? Y N. 3. Has the patient received 6 months or more of therapy? Y N
Prior Authorization MERC CARE PLA Weight Reduction Medications (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date.
More informationManaging Obesity as a Disease. Disclosure. Objectives
Managing Obesity as a Disease Ji Hyun Chun (CJ), PA-C, BC-ADM OptumCare Medical Group: Endocrinology, Irvine, CA President, American Society of Endocrine PAs none Disclosure Objectives Recognize obesity
More informationObesity and Bariatric Surgery
Obesity and Bariatric Surgery Disclosure Nothing to disclose Subhashini Ayloo MD, MPH, FACS Associate Professor of Surgery Director of MIS HPB/LT Rutgers, New Jersey Medical School March 24 th, 2017 Overview
More informationIdentification, Evaluation, and Treatment of Overweight and Obesity in Adults
Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making
More informationOBESITY: FACTS AND FICTIONS
Robert B. Baron MD MS Prevalence of Obesity (Adults) Obesity: 33.8% Men: 32.2% Women: 35.5% Professor of Medicine Associate Dean for GME and CME Director, UCSF Osher Mini Med School Director, UCSF Weight
More informationIdentification, Evaluation, and Treatment of Overweight and Obesity in Adults Clinical Practice Guideline MedStar Health
Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making
More informationObesity: The Role of Pharmacotherapy The Annual Women s & Children s Health Update Saturday 17th February 2018 Benefits of modest weight loss 3-10%
Obesity: The Role of Pharmacotherapy Professor John B Dixon, MBBS PhD Professorial Research Fellow Head, Clinical Obesity Research Baker IDI Heart & Diabetes Institute Melbourne, Australia The Annual Women
More informationA Pharmacotherapeutic Option for Chronic Weight Management
BELVIQ A Pharmacotherapeutic Option for Chronic Weight Management INDICATION BELVIQ is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in
More informationSAXENDA PRODUCT MONOGRAPH. liraglutide. 6 mg/ml. Solution for Injection in a pre-filled pen. Human Glucagon Like Peptide-1 (GLP-1) Weight Management
PRODUCT MONOGRAPH SAXENDA liraglutide 6 mg/ml Solution for Injection in a pre-filled pen Human Glucagon Like Peptide-1 (GLP-1) Weight Management Novo Nordisk Canada Inc. 300-2680 Skymark Avenue Mississauga,
More informationImportant Safety Information for Adlyxin (lixisenatide) injection
A GLP-1 receptor agonist (RA) Adlyxin (lixisenatide) injection 20 mcg Information To Help Answer Patients Questions This booklet contains information about Adlyxin to help you answer patients questions
More informationNew Drug Targets for the Treatment of Obesity
nature publishing group New Drug Targets for the Treatment of Obesity AG Powell 1, CM Apovian 2 and LJ Aronne 3 There is a huge void in the current pharmacological treatment options for obesity. This gap
More informationPRESCRIPTION WEIGHT-LOSS MEDICATION. Najla Lakkis, MD, MPH Oct 6, 2012
PRESCRIPTION WEIGHT-LOSS MEDICATION Najla Lakkis, MD, MPH Oct 6, 2012 Epidemy of Obesity Lebanon: the prevalence of overweight and obesity in the adults aged 20 years reached 37.0% and 11.0% respectively
More informationShould I Stand Watch?
Should I Stand Watch? A Review of New Medications and Herbal Products and the Possible Effects on Licensed Operators Michael L. Zaruba, M.D. Auburn Family Health Center NPPD/Cooper Nuclear Station Objectives
More informationPhentermine Hydrochloride
Weight Loss Medications Phentermine Hydrochloride Drug Enforcement Agency DEA: Schedule IV drug Indications: It is approved as monotherapy as a weight loss drug Doses To be taken once a day in the morning
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationOctober Physician s Guide to. Obesity. In collaboration with
October 2013 Physician s Guide to Obesity In collaboration with Dear Healthcare Professional, Welcome to the Cleveland Clinic Physician s Guide to Obesity, an information-packed tool brought to you by
More informationVictoza (liraglutide) solution for injection 6 mg/ml
Page: 1 of 11 Victoza (liraglutide) solution for injection 6 mg/ml Summary of the risk management plan (RMP) for Victoza Author: Novo Nordisk Pharma AG Page: 2 of 11 Table of Contents Page Table of Contents...
More informationNon-surgical Treatment for Adult Obesity
Non-surgical Treatment for Adult Obesity Kathy Foreman, CNP Comprehensive Weight Management and Bariatric Surgery Program The Ohio State University Wexner Medical Center Objectives Definition, prevalence
More informationPharmacotherapy of Obesity
C H A P T E R 157 Pharmacotherapy of Obesity Sachin Kumar Jain, Rati Singh, Ramesh Aggarwal, Ritika Sud INTRODUCTION Obesity has emerged as a global public health crisis and obesity rates have sharply
More informationOverweight and Obesity on the Menu. Marwan Akel, Pharm. D, MPH Clinical Assistant Professor School of Pharmacy Lebanese International University
Overweight and Obesity on the Menu Marwan Akel, Pharm. D, MPH Clinical Assistant Professor School of Pharmacy Lebanese International University Prevention The most efficient and cost-effective approach
More informationMedical Treatments in Obesity. Joseph Leung, BSc (Hons), MD, FRCPC, ABIM UBC Endocrinology Fellow PGY-5 Thursday, April 19 th, 2018
Medical Treatments in Obesity Joseph Leung, BSc (Hons), MD, FRCPC, ABIM UBC Endocrinology Fellow PGY-5 Thursday, April 19 th, 2018 Disclosures I have no current or past relationships with commercial entities
More informationAACE/ACE ALGORITHM FOR THE MEDICAL CARE OF PATIENTS WITH OBESITY
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY AACE/ACE ALGORITHM FOR THE MEDICAL CARE OF PATIENTS WITH OBESITY O B E S I T Y R E S O U R C E C E N T E R CO M M I T
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationattempts to commit suicide acting aggressive, being angry, or violent
Medication Guide CONTRAVE (CON-trayv) (naltrexone HCl and bupropion HCl) Extended-Release Tablets Read this Medication Guide before you start taking CONTRAVE and each time you get a refill. There may be
More informationAPhA March 2016 Annual Meeting Obesity Cases
APhA March 2016 Annual Meeting Obesity Cases Case #1 Pam is a 47 yo obese Caucasian woman; grade school teacher with a history of HTN, HoTR, and depression who presents for her annual physical. CC: I m
More informationNEW DEVELOPMENTS IN ASSESSMENT AND TREATMENT OF OBESITY
Prevalence of Obesity (Adults)! Obesity: 33.8% Men: 32.2% Women: 35.5% Overweight + obesity: 68% Men: 72.3% Women: 64.1% Severe Obesity: 6% Flegal JAMA 2010 Men and Women Aged 40 to 59 Years in 1999-2000
More informationObesity Epidemic (Approaches to its Treatment) Ricardo Correa, M.D., Es.D., F.A.C.P., F.A.C.R., C.M.Q.
Obesity Epidemic (Approaches to its Treatment) Ricardo Correa, M.D., Es.D., F.A.C.P., F.A.C.R., C.M.Q. Assistant Professor of Medicine University of Arizona College of Medicine-Phoenix and The Warren Alpert
More informationNDA QSYMIA (phentermine and topiramate) Extended-release Capsules [Category: anorectic and antiepileptic] VIVUS, Inc.
Initial REMS approval 07/2012 NDA 22580 QSYMIA (phentermine and topiramate) Extended-release Capsules [Category: anorectic and antiepileptic] VIVUS, Inc. Contact: VIVUS Medical Information Phone: 1-888-998-4887
More informationB.C. Drug and Poison Information Centre 655 West 12th Avenue, Vancouver, BC V5Z 4R4 Phone: (604) ; Fax: (604) Volume 31 (2) 2011
Volume 31 (2) 2011 Editor and author: Barbara Cadario, BSc(Hon), BScPhm., MSc Chairman, Medical Review Laird Birmingham, MD, MHSc, FRCP(C) SYNONYM: NN2211 TRADE NAME: Victoza CLASSIFICATION GLP-1 receptor
More informationCURRENT STRATEGIES IN OBESITY
Prevalence of Obesity (Adults)! Obesity: 33.8% Men: 32.2% Women: 35.5% Overweight + obesity: 68% Men: 72.3% Women: 64.1% Severe Obesity: 6% Flegal JAMA 2010 Men and Women Aged 40 to 59 Years in 1999-2000
More informationTreatment of Obesity: Diets, Drugs and Surgery
Treatment of Obesity: Diets, Drugs and Surgery Disclosures None Michelle Guy, MD Professor Clinical Medicine University of California San Francisco Diplomate American Board of Obesity Medicine Objectives
More informationCopyright 2017 by Sea Courses Inc.
Appetite Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical,
More informationTreating Patients with PRE- DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background
Treating Patients with PRE- DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationPharmacotherapy for obesity: What you need to know
CURRENT DRUG THERAPY CME CREDIT LEARNING OBJECTIVE: Readers will prescribe and monitor pharmacotherapy as indicated to help patients lose weight SOPHIE BERSOUX, MD, MPH Assistant Professor of Medicine,
More informationNew Strategies in Weight Loss
New Strategies in Weight Loss Gary D. Foster, PhD Chief Scientific Officer Weight Watchers International Adjunct Professor of Psychology in Psychiatry Center for Weight and Eating Disorders Perelman School
More informationPast, Present and Future of Pharmacotherapy for Obesity
Past, Present and Future of Pharmacotherapy for Obesity Dan Bessesen, MD Chief of Endocrinology; Denver Health Medical Center Professor of Medicine, University of Colorado School of Medicine Daniel.Bessesen@ucdenver.edu
More information